Skip to main content
SpringerLink
Log in

Overcoming ‘Ageism’ Bias in the Treatment of Hypercholesterolaemia

A Review of Safety Issues with Statins in the Elderly

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Atherosclerosis is a progressive, lifelong condition that is the leading cause of death among middle-aged and elderly individuals aged ≥65 years. Up to 80% of elderly patients are found to have evidence of obstructive coronary heart disease at autopsy. Demographic trends, including the advancing median age and life expectancy of Western societies, suggest that a large share of the burden of atherosclerotic plaque is likely to be borne by elderly individuals. These trends are in part due to increases in a number of chronic diseases associated with adverse cardiovascular outcomes, including metabolic syndrome, diabetes mellitus and chronic kidney disease. Because the elderly have a higher attributable risk of coronary heart disease as a result of hypercholesterolaemia, more coronary deaths and overall events can be prevented via treatment in this age group compared with younger persons with hypercholesterolaemia. The efficacy, safety and tolerability of HMG-CoA reductase inhibitors (statins) have been confirmed in randomised, controlled, multicentre trials involving large numbers of patients aged ≥65 years. Although muscle symptoms such as myalgia are relatively common adverse events, more severe signs of myolysis such as myopathy and rhabdomyolysis are rare, but their risk is elevated by conditions (e.g. concomitant medications) that increase the systemic exposure of these agents. Statins differ in their susceptibility to increases in systemic exposure, but most statins have been demonstrated to be well tolerated and safe when administered to elderly patients. These favourable clinical findings should help clinicians counter highly prevalent ‘ageism’ bias in statin prescribing, whereby elderly patients, particularly those at highest cardiovascular risk, are often denied the benefits of statins without any meaningful foundation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Table I
Table II
Fig. 3
Fig. 4
Table III
Table IV
Table V

Similar content being viewed by others

Article 05 August 2014

Benjamin H. Han, Yitzchak Weinberger & David Sutin

References

  1. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735–43

    Article  PubMed  Google Scholar 

  2. Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996; 94: 2381–8

    Article  PubMed  CAS  Google Scholar 

  3. Collins R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  4. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67

    Article  PubMed  CAS  Google Scholar 

  5. Grundy SM, Cleeman JI, Rifkind BM, et al. Cholesterol lowering in the elderly population: coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159: 1670–8

    Article  PubMed  CAS  Google Scholar 

  6. Desai MM, Zhang P, Hennessy CH. Surveillance for morbidity and mortality among older adults: United States, 1995-1996 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss4808a2.htm [Accessed 2005 February 7]

  7. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 1994; 139: 1164–79

    PubMed  CAS  Google Scholar 

  8. Kagansky N, Levy S, Berner Y, et al. Cholesterol lowering in the older population: time for reassessment? QJM 2001; 94: 457–63

    Article  PubMed  CAS  Google Scholar 

  9. Batchelor WB, Jollis JG, Friesinger GC. The challenge of health care delivery to the elderly patient with cardiovascular disease: demographic, epidemiologic, fiscal, and health policy implications. Cardiol Clin 1999; 17: 1–15, vii

    Article  PubMed  CAS  Google Scholar 

  10. US Census Bureau: US interim projections by age, sex, race, and Hispanic origin. 2004 [online]. Available from URL: http://www.census.gov/ipc/www/usinterimproj/ [Accessed 2005 January 25]

  11. Grundy SM. Age as a risk factor: you are as old as your arteries. Am J Cardiol 1999; 83: 1455–7, A7

    Article  PubMed  CAS  Google Scholar 

  12. Rumberger JA, Sheedy PF, Breen JF, et al. Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Mayo Clin Proc 1996; 71: 369–77

    Article  PubMed  CAS  Google Scholar 

  13. Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation 1995; 92: 2157–62

    Article  PubMed  CAS  Google Scholar 

  14. Rumberger JA, Schwartz RS, Simons DB, et al. Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol 1994; 73: 1169–73

    Article  PubMed  CAS  Google Scholar 

  15. Schmermund A, Baumgart D, Gorge G, et al. Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity. J Am Coll Cardiol 1998; 31: 1267–73

    Article  PubMed  CAS  Google Scholar 

  16. Guerci AD, Spadaro LA, Popma JJ, et al. Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults. Am J Cardiol 1997; 79: 128–33

    Article  PubMed  CAS  Google Scholar 

  17. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444–9

    Article  PubMed  Google Scholar 

  18. American Heart Association. Women and cardiovascular diseases: statistics. Statistical fact sheet: populations [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?.identifier = 3000941 [Accessed 2005 August 3]

  19. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004; 43: 900–21

    Article  PubMed  Google Scholar 

  20. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962–7

    Article  PubMed  CAS  Google Scholar 

  21. Welty FK. Preventing clinically evident coronary heart disease in the postmenopausal woman. Menopause 2004; 11: 484–94

    Article  PubMed  Google Scholar 

  22. Mosca L, Ferris A, Fabunmi R, et al. Tracking women’s awareness of heart disease: an American Heart Association national study. Circulation 2004; 109: 573–9

    Article  PubMed  Google Scholar 

  23. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–95

    Article  PubMed  CAS  Google Scholar 

  24. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19: 1045–52

    Article  PubMed  Google Scholar 

  25. National Kidney Foundation. National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41: S1–S92

    Google Scholar 

  26. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–69

    Article  PubMed  Google Scholar 

  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72

    Article  PubMed  CAS  Google Scholar 

  28. Adult Treatment Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–421

    Google Scholar 

  29. Fedder DO, Koro CE, L’Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105: 152–6

    Article  PubMed  Google Scholar 

  30. Levy AR, O’Brien BJ, McMullen E, et al. Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000. Can J Cardiol 2003; 19: 665–9

    PubMed  Google Scholar 

  31. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89: 417–21

    Article  PubMed  CAS  Google Scholar 

  32. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 15–9

    Article  PubMed  CAS  Google Scholar 

  33. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864–70

    Article  PubMed  CAS  Google Scholar 

  34. Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002; 88: 25–9

    Article  PubMed  CAS  Google Scholar 

  35. Lalouschek W, Lang W, Greisenegger S, et al. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003; 34: 105–10

    Article  PubMed  CAS  Google Scholar 

  36. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176–80

    Article  PubMed  CAS  Google Scholar 

  37. Volpato S, Leveille SG, Corti MC, et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc 2001; 49: 1142–7

    Article  PubMed  CAS  Google Scholar 

  38. Staessen J, Amery A, Birkenhager W, et al. Is a high serum cholesterol level associated with long survival in elderly hypertensives? J Hypertens 1990; 8: 755–61

    Article  PubMed  CAS  Google Scholar 

  39. Kronmal RA, Cain KC, Ye Z, et al. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med 1993; 153: 1065–73

    Article  PubMed  CAS  Google Scholar 

  40. Raiha I, Marniemi J, Puukka P, et al. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997; 17: 1224–32

    Article  PubMed  CAS  Google Scholar 

  41. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119–23

    Article  PubMed  CAS  Google Scholar 

  42. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35

    Article  PubMed  CAS  Google Scholar 

  43. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Persp Clin Hepatol 2005; 41: 690–5

    CAS  Google Scholar 

  44. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III-50–III-57

    Article  CAS  Google Scholar 

  45. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681–90

    Article  PubMed  CAS  Google Scholar 

  46. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408–16

    Article  PubMed  CAS  Google Scholar 

  47. Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002; 11: 48–55

    Article  PubMed  Google Scholar 

  48. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581–5

    PubMed  Google Scholar 

  49. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539–40

    Article  PubMed  Google Scholar 

  50. AstraZeneca: Crestor® (rosuvastatin calcium) [online]. Available from URL: http://www.astrazeneca-us.com/pi/crestor.pdf [Accessed 2005 February 18]

  51. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140–6

    Article  PubMed  CAS  Google Scholar 

  52. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505–12

    Article  PubMed  CAS  Google Scholar 

  53. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–90

    Article  PubMed  CAS  Google Scholar 

  54. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120–2

    Article  PubMed  CAS  Google Scholar 

  55. Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004; 292: 2622–31

    Article  PubMed  CAS  Google Scholar 

  56. Insull W Jr, Isaacsohn J, Kwiterovich P. Efficacy and safety of cerivastatin 0.8mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J Int Med Res 2000; 28: 47–68

    PubMed  CAS  Google Scholar 

  57. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423–9

    Article  PubMed  CAS  Google Scholar 

  58. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96

    Article  PubMed  CAS  Google Scholar 

  59. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58

    Article  PubMed  CAS  Google Scholar 

  60. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22

    Article  PubMed  CAS  Google Scholar 

  61. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994; 74: 667–73

    Article  PubMed  CAS  Google Scholar 

  62. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30

    Article  PubMed  CAS  Google Scholar 

  63. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TeXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074–9

    Article  PubMed  CAS  Google Scholar 

  64. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  65. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of L D L lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758–64

    Article  PubMed  CAS  Google Scholar 

  66. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419–25

    Article  PubMed  CAS  Google Scholar 

  67. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–8

    Article  PubMed  CAS  Google Scholar 

  68. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5

    Article  PubMed  CAS  Google Scholar 

  69. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronaryheart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220–8

    Article  PubMed  Google Scholar 

  70. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504

    Article  PubMed  CAS  Google Scholar 

  71. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215–22

    Article  PubMed  CAS  Google Scholar 

  72. Herd JA. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am J Med 1998; 104: 42S–9S

    Article  PubMed  CAS  Google Scholar 

  73. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278–86

    Article  PubMed  CAS  Google Scholar 

  74. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263–70

    Article  PubMed  CAS  Google Scholar 

  75. Post-CABG Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336: 153–62

  76. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679–87

    Article  PubMed  CAS  Google Scholar 

  77. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331: 1331–7

    Article  PubMed  CAS  Google Scholar 

  78. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–57

    Google Scholar 

  79. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317–26

    Article  PubMed  CAS  Google Scholar 

  80. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341–6

    Article  PubMed  CAS  Google Scholar 

  81. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9

    Article  PubMed  CAS  Google Scholar 

  82. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387–92

    Article  PubMed  CAS  Google Scholar 

  83. PMSG Investigators. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72: 1031–7

    Google Scholar 

  84. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  85. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8

    Google Scholar 

  86. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16

    Article  PubMed  Google Scholar 

  87. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024–31

    Article  PubMed  CAS  Google Scholar 

  88. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 415–33

    Article  PubMed  Google Scholar 

  89. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374–80

    Article  PubMed  CAS  Google Scholar 

  90. Perger L, Kohler M, Fattinger K, et al. Fatal liver failure with atorvastatin [letter]. J Hepatol 2003; 39: 1096–107

    Article  Google Scholar 

  91. Tolman KG. Defining patient risk from expanded preventive therapies. Am J Cardiol 2000; 85: 15E–9E

    Article  PubMed  CAS  Google Scholar 

  92. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation from drug induced liver injury in the United States. Liver Transpl 2004; 10: 1018–23

    Article  PubMed  Google Scholar 

  93. Graziadei IW, Obermoser GE, Sepp NT, et al. Drug-induced lupus-like syndrome associated severe autoimmune hepatitis. Lupus 2003; 12: 409–12

    Article  PubMed  CAS  Google Scholar 

  94. Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastro Hepatol 2003; 15: 921–4

    Article  Google Scholar 

  95. Parke-Davis. Lipitor® (atorvastatin calcium): US prescribing information [online]. Available from URL: http://www.pfizer.com/download/uspi_lipitor.pdf. [Accessed 2005 February 18]

  96. Novartis. Lescol®, Lescol® XL (fluvastatin sodium): US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/Lescol.pdf. [Accessed 2005 February 18]

  97. Farnier M, Bortolini M, Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 91: 238–40

    Article  PubMed  CAS  Google Scholar 

  98. Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000; 150: 429–36

    Article  PubMed  CAS  Google Scholar 

  99. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000; 86: 759–63

    Article  PubMed  CAS  Google Scholar 

  100. Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol 2003; 12: 225–31

    PubMed  Google Scholar 

  101. Lye M, Valacio R, Reckless JP, et al. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Coron Artery Dis 1998; 9: 583–90

    Article  PubMed  CAS  Google Scholar 

  102. Bruckert E, Hayem G, Dejager S, et al. Risk of muscular symptoms with high dosage statin therapy in 7924 hyperlipidemic patients in French clinical practice. American College of Cardiology; 2005 March 6-9; Orlando, FL

    Google Scholar 

  103. Serruys PW, De Feyter PJ, Benghozi R, et al. The Lescol® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001; 4: 165–72

    PubMed  Google Scholar 

  104. Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002; 89: 231–3

    Article  PubMed  CAS  Google Scholar 

  105. Bristol-Myers Squibb: Pravachol® (pravastatin sodium). US prescribing information [online]. Available from URL: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=56 [Accessed 2005 February 18]

  106. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716–23

    Article  PubMed  CAS  Google Scholar 

  107. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134: 931–40

    PubMed  CAS  Google Scholar 

  108. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94: 882–8

    Article  PubMed  CAS  Google Scholar 

  109. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60

    Article  PubMed  CAS  Google Scholar 

  110. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMGCoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116–21

    Article  PubMed  CAS  Google Scholar 

  111. Galson SK for the US Food and Drug Administration. Rejection of Public Citizen petition (cited 3/11/05) Docket No. 2004P-0113CP1 [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf. [Accessed 2005 August 30]

  112. Brewer HB. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 23K–9K

    Article  PubMed  CAS  Google Scholar 

  113. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52–60

    Article  PubMed  CAS  Google Scholar 

  114. Alsheikh-Ali A, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111: 3051–7

    Article  PubMed  Google Scholar 

  115. Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111: 3016–9

    Article  PubMed  Google Scholar 

  116. Merck. Zocor® (simvastatin): US prescribing information [online]. Available from URL: http://www.zocor.com/zocor/shared/documents/english/pi.pdf [Accessed 2005 February 18]

  117. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211–8

    Article  PubMed  CAS  Google Scholar 

  118. Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004; 21: 1025–32

    Article  PubMed  CAS  Google Scholar 

  119. Abbott TriCor® (fenofibrate): US prescribing information [online]. Available from URL: http://www.rxabbott.com/pdf/tricorpi.pdf [Accessed 2005 March 25]

  120. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288–95

    Article  PubMed  CAS  Google Scholar 

  121. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003; 17: 265–85

    Article  PubMed  CAS  Google Scholar 

  122. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417–26

    Article  PubMed  CAS  Google Scholar 

  123. Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999; 69: 237–44

    Article  PubMed  CAS  Google Scholar 

  124. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30(11): 1280–7

    Article  PubMed  CAS  Google Scholar 

  125. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410–6

    PubMed  CAS  Google Scholar 

  126. Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538–44

    Article  PubMed  CAS  Google Scholar 

  127. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455–63

    Article  PubMed  CAS  Google Scholar 

  128. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80A–3A

    Article  PubMed  CAS  Google Scholar 

  129. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122–9

    Article  PubMed  CAS  Google Scholar 

  130. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13–20

    Article  PubMed  CAS  Google Scholar 

  131. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90: 50K–60K

    Article  PubMed  CAS  Google Scholar 

  132. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–92

    Article  PubMed  CAS  Google Scholar 

  133. Zhao X-Q, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93: 307–12

    Article  PubMed  CAS  Google Scholar 

  134. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672–8

    Article  PubMed  CAS  Google Scholar 

  135. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol 1994; 73: 25D–9D

    Article  PubMed  CAS  Google Scholar 

  136. Pasternak RC, Brown LE, Stone PH, et al. for the Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 529–40

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Jacobson has served as a consultant for AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Novartis, Pfizer, Reliant, and Schering-Plough. Assistance in manuscript preparation was provided by Stephen W. Gutkin, Rete Biomedical Communications Corp. (Ridgewood, NJ). Dr Jacobson received partial funding for this manuscript from an unrestricted educational grant from Reliant Pharmaceuticals, Liberty Corner, New Jersey, USA.

Author information

Authors and Affiliations

  1. Office of Health Promotion and Disease Prevention, Emory University School of Medicine, 49 Jesse Hill Jr Dr, Atlanta, Georgia, 30303, USA

    Terry A. Jacobson

Authors
  1. Terry A. Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terry A. Jacobson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobson, T.A. Overcoming ‘Ageism’ Bias in the Treatment of Hypercholesterolaemia. Drug-Safety 29, 421–448 (2006). https://doi.org/10.2165/00002018-200629050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629050-00005

Keywords

Search

Navigation